HIT Consultant – Read More

What You Should Know

• The Launch: ConcertAI has released Accelerated Clinical Trials (ACT), an enterprise platform designed to automate the clinical trial lifecycle using “Agentic AI”—autonomous software that performs tasks rather than just generating text.
• The Promise: By integrating proprietary Real-World Data (RWD) with AI workflows, the platform claims it can shorten trial timelines by 10 to 20 months and reduce costly protocol amendments by 50%.
• The Tech: Built on the CARAai infrastructure, the system deploys purpose-built agents to handle complex reasoning tasks like site selection, feasibility assessments, and competitive analysis, effectively acting as a “digital co-pilot” for trial sponsors.

The Shift from “Generative” to “Agentic”

The distinction between Generative AI and Agentic AI is the defining tech narrative of 2026. While a generative model can write a trial protocol, an agentic model can analyze the protocol, compare it against thousands of real-world patient records, predict failure points, and suggest a better site list.

Built on ConcertAI’s proprietary CARAai architecture, the ACT platform uses these agents to automate the most friction-heavy parts of a study:

• Protocol Design: By using AI to validate feasibility before a trial starts, ACT claims to reduce protocol amendments by approximately 50%.
• Site Selection: By automating the validation of research sites, the platform can reportedly cut selection and activation timelines by 25-50%.

The Math of Efficiency

The boldest claim in ConcertAI’s announcement is the potential to shorten overall trial timelines by 10 to 20 months. In an industry where the patent clock is always ticking, saving nearly two years on a clinical trial is transformative. This efficiency is achieved by solving the “design flaw” problem cited by the Tufts Center for the Study of Drug Development. When 76% of trials need to be fixed after they start, the system is fundamentally reactive.

ConcertAI’s approach uses AI-driven probability forecasts to make the process proactive. By simulating enrollment goals and feasibility against Real-World Data (RWD), the system ensures that the trial designed on paper can actually be executed in the real world.